Cidara Therapeutics, Inc.
CDTX
株式のランク
#3184
Cidara Therapeutics, Inc. is a biotechnology company specializing in the... Cidara Therapeutics, Inc. is a biotechnology company specializing in the creation, advancement, and commercialization of extended-duration anti-infective drugs. Their mission targets the prevention and treatment of infectious diseases and certain cancers within the U.S. Their primary therapeutic candidate, rezafungin acetate, is an innovative echinocandin antifungal designed to combat and avert severe fungal infections such as candidemia and invasive candidiasis, conditions known for their high fatality rates. Additionally, Cidara utilizes its Cloudbreak platform to engineer conjugated therapies aimed at preventing and treating influenza as well as various other viral illnesses, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), and SARS-CoV-2, the pathogen behind COVID-19. Originally incorporated in 2012 as K2 Therapeutics, Inc., the company adopted its current name, Cidara Therapeutics, Inc., in July 2014. Its operations are headquartered in San Diego, California.
株価
$221.38
最終同期: 2026-01-08
時価総額
$5.61B
変化（1日）
0.00%
変化（1年）
120.15%
国
US
取引 Cidara Therapeutics, Inc. (CDTX)
カテゴリー
Healthcare
Cidara Therapeutics, Inc.（CDTX）の発行済株式数
September 2025 時点の発行済株式数 15.55M
Cidara Therapeutics, Inc. の最新の財務報告および株価によると、現在の発行済株式数は 15.55M です。December 2023 の終わりには、同社は 4.37M 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
Cidara Therapeutics, Inc.（CDTX）の発行済株式数の履歴（2012 ～ 2026）
各年末時点の発行済株式数
| 年 | 発行済株式数 | 変化 |
|---|---|---|
| 2026 (TTM) | 15.55M | 144.86% |
| 2024 | 6.35M | 45.25% |
| 2023 | 4.37M | 25.15% |
| 2022 | 3.49M | 33.24% |
| 2021 | 2.62M | 26.16% |
| 2020 | 2.08M | 38.83% |
| 2019 | 1.50M | 15.71% |
| 2018 | 1.29M | 47.82% |
| 2017 | 875.04K | 20.79% |
| 2016 | 724.45K | 5.22% |
| 2015 | 688.48K | 1,579.52% |
| 2014 | 40.99K | 153.29% |
| 2013 | 16.18K | -8.65% |
| 2012 | 17.72K | 0.00% |
類似企業や競合他社の発行済株式数
| 企業 | 発行済株式数 | 差 | 国 |
|---|---|---|---|
| 253.90M | 1,533.07% |
US
|
|
| 396.00M | 2,447.05% |
US
|
|
| 478.91M | 2,980.33% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | 299.97% |
NL
|
